iPSC Heart Tissue Model Reveals SGLT2 Inhibitors Reverse Diastolic Dysfunction
Researchers built a human cell-based model of HFpEF and found SGLT2 inhibitors restore relaxation via the eNOS-NO-cGMP-PKG anti-inflammatory pathway.
Summary
Heart failure with preserved ejection fraction (HFpEF) is a common, poorly understood condition where the heart pumps normally but relaxes poorly. Researchers created miniature human heart tissues from induced pluripotent stem cells and exposed them to conditions mimicking HFpEF — high fatty acids and a nitric oxide blocker. These engineered tissues showed impaired relaxation, elevated heart-failure biomarkers, and abnormal calcium signaling while maintaining normal contraction. When tested against existing heart-failure drugs, an SGLT2 inhibitor — the same drug class used for diabetes and increasingly for heart failure — was the most effective at restoring relaxation. The mechanism involved recovering the eNOS-nitric oxide-cGMP signaling pathway, reducing inflammation. This human cellular platform could accelerate drug discovery for a condition that currently lacks effective treatments.
Detailed Summary
Heart failure with preserved ejection fraction (HFpEF) represents roughly half of all heart failure cases and carries a poor prognosis, yet no therapy has convincingly improved outcomes. A key challenge has been the lack of human cellular models that accurately replicate the disease's defining feature: impaired cardiac relaxation (diastolic dysfunction) despite normal pumping strength.
Researchers from Keio University, Fujita Health University, and Kyoto University developed human engineered heart tissues (hEHTs) using induced pluripotent stem cells (iPSCs). To mimic HFpEF pathophysiology, they cultured these tissues under high fatty acid concentrations combined with L-NAME, a nitric oxide synthase inhibitor — conditions that recreate the metabolic and inflammatory stress seen in HFpEF patients.
The resulting tissues faithfully replicated the HFpEF phenotype: relaxation function was markedly impaired while contraction remained preserved, BNP (a key heart-failure biomarker) was secreted at high levels, calcium handling was abnormal, and structural signs of heart failure were evident. This mirrors clinical HFpEF far more closely than prior animal or non-human models.
The team then tested multiple established heart-failure drugs on the model. SGLT2 inhibitors — a drug class originally developed for type 2 diabetes and now approved for heart failure — stood out by significantly improving diastolic dysfunction. Mechanistically, SGLT2 inhibition restored the eNOS-nitric oxide-cGMP-PKG signaling axis, exerting anti-inflammatory effects that underpinned the functional recovery.
These findings have meaningful implications for longevity medicine. HFpEF is fundamentally an age-related disease driven by metabolic dysfunction, chronic inflammation, and vascular stiffness. Having a validated human tissue model accelerates mechanistic research and drug screening. The SGLT2 inhibitor finding provides cellular-level mechanistic support for their clinical benefit in HFpEF. Caveats include reliance on the abstract alone and the inherent limitations of in vitro models versus complex in vivo physiology.
Key Findings
- iPSC-derived heart tissues replicated HFpEF: impaired relaxation, preserved contraction, and elevated BNP biomarker.
- SGLT2 inhibitors outperformed other heart-failure drugs in restoring diastolic relaxation in the model.
- SGLT2 inhibition worked via eNOS-NO-cGMP-PKG pathway recovery, producing anti-inflammatory effects.
- Abnormal calcium transients were observed, linking metabolic stress to functional diastolic impairment.
- This human cellular HFpEF platform provides a new tool for drug discovery and mechanistic research.
Methodology
Human iPSCs were differentiated into cardiomyocytes and formed into three-dimensional engineered heart tissues. HFpEF-like diastolic dysfunction was induced by culturing tissues with high fatty acids and L-NAME (an eNOS inhibitor). Multiple existing heart-failure drugs were then applied to assess functional rescue.
Study Limitations
This summary is based on the abstract only, as the full paper was not accessible. The model is in vitro and may not capture the full systemic complexity of HFpEF in aging patients. Two authors hold equity in a related cardiac regenerative medicine company, representing a potential conflict of interest.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: